Standard Biotools (LAB) Divestments (2020 - 2026)

Standard Biotools (LAB) reported Divestments of $363.2 million for Q1 2026, up 18061.1% quarter-over-quarter from $2.0 million in Q3 2021.

Standard Biotools (LAB) Divestments (2020 - 2026) Analysis & Trends

Standard Biotools (LAB) has 3 years of Divestments data on file, last reported at $363.2 million in Q1 2026.

Divestments for Q1 2026 came in at $363.2 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $363.2 million (changed N/A YoY), and the FY2021 annual result was $1.3 million, down 93.73% from the prior year.
Divestments improved to $363.2 million in Q1 2026 per LAB's latest filing, from $2.0 million in the prior quarter.
Over five years, Divestments peaked at $363.2 million in Q1 2026 and troughed at $363.2 million in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Divestments (Qtr)
1	Abbott Laboratories	154.42 Bn	147.76 Bn	6.27 Bn	-
2	Stryker	118.12 Bn	115.25 Bn	3.81 Bn	-
3	Medtronic	101.72 Bn	93.55 Bn	5.76 Bn	-
4	Boston Scientific	67.19 Bn	65.98 Bn	3.61 Bn	-
5	Edwards Lifesciences	50.69 Bn	47.02 Bn	1.29 Bn	-
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn	9.37 Mn
7	Dexcom	28.09 Bn	26.97 Bn	750.30 Mn	-
8	GE HealthCare Technologies	28.08 Bn	26.02 Bn	1.98 Bn	-
9	Steris	19.80 Bn	19.37 Bn	697.10 Mn	-
10	Standard Biotools	319.06 Mn	-136.11 Mn	11.31 Mn	363.22 Mn

Download Data